Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospital, Geneva | OTHER |
| MDSS | UNKNOWN |
Not provided
Not provided
The goal of this clinical trial is to find out whether using a personalized breast holder (called VENUS SHELLâ„¢) can improve positioning and patient comfort during prone radiotherapy (radiotherapy given while the patient lies on her stomach).
The main goals of the study are:
Participants will:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| VENUS SHELLâ„¢ arm | Experimental | VENUS SHELLâ„¢ is used for radiotherapy planning and radiotherapy tratment (Accelerated Partial Breast Radiotherapy) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| VENUS SHELLâ„¢ immobilization device | Device | VENUS SHELLâ„¢ is used for Accelerated Partial Breast Irradiation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility outcome: Time (days) between surface scan data received by HeroSupport and arrival of the VENUS SHELLâ„¢ at the clinical site | Treatment set-up (up to 21 days) | |
| Performance outcomes: radiotherapy delivered within 15 minutes timeslot and patient positioning accuracy within 2 mm | Radiotherapy time includes patient positioning and treatment. Patient positioning accuracy is measured though displacement via Tattoos and Image-Guided Radiation Therapy imaging | Study treatment (10 days) |
| Safety outcome: number of medical device-related Adverse Events as assessed by CTCAE v5.0 | Through study completion (an average of 3 months) |
| Measure | Description | Time Frame |
|---|---|---|
| Patients' comfort (questionnaires) | A first set of questions is rated on a 5-point scale ranging from 1 (strongly disagree) to 5 (strongly agree). A second set of questions is rated on a 4-point scale ranging from 1 (not at all) to 4 (very). | Treatment set-up (up to 21 days) and study treatment (10 days) |
Not provided
INCLUSION Criteria:
For invasive breast cancer only:
For ductal carcinoma in situ only:
EXCLUSION Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Giovanna Dipasquale | Contact | +41(0)783349987 | giovanna@herosupport.ch | |
| Cristina Riccadonna | Contact | +41(0)223794650 | clinical@herosupport.ch |
| Name | Affiliation | Role |
|---|---|---|
| Naamit Gerber, MD | NYU Langone Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| NYU Grossman School of Medicine | Recruiting | New York | New York | 10016 | United States |
Not provided
| ID | Term |
|---|---|
| D002285 | Carcinoma, Intraductal, Noninfiltrating |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Evaluate ease of use and overall satisfaction of using the VENUS SHELL (questionnaires) |
A set of questions rated on a 5-point scale ranging from 1 (strongly disagree) to 5 (strongly agree). |
| Study treatment (10 days) |
| In-vivo dosimetry measured with thermoluminescent dosimeters (TLDs) | Comparison between expected and measured dose to the skin | Radiotherapy treatment first session, up to last session (10 days) |
| D009369 | Neoplasms |
| D000071960 | Breast Carcinoma In Situ |
| D002278 | Carcinoma in Situ |
| D018299 | Neoplasms, Ductal, Lobular, and Medullary |